Programme

This meeting will be attended by people from 28 different countries spread across 17 time zones! Please plan your attendance carefully, taking into consideration that all times shown in the programme below are German times (CEST).

• Thursday
  23 September THU
  23
  Sep
• Friday
  24 September FRI
  24
  Sep
• List of
  Posters List of
  Posters

• 14:00-14:30

  Registration & Welcome

  14:30-15:30

  Keynote Lecture 1

  Chair: Torsten Doenst (Jena, Germany)

  Howy Jacobs (Tampere, Finland)

  Fahrenheit 101 - mitochondria are not as cool as we imagined

  15:30-16:30

  Session 1

  Chairs: Estelle Heyne (Jena, Germany) & Howy Jacobs (Tampere, Finland)

  15:30-15:50

  Anne Garnier (Chatenay-Malabry, France)

  Metabolic and non-metabolic effects of the cardiac inducible deletion of AMPKalpha2 in male and female mice

  15:50-16:10

  Zoltan Arany (Philadelphia, PA, USA)

  Extra-cardiac BCAA catabolism lowers blood pressure and protects from heart failure

  16:10-16:20

  Short talk: Jan Dudek (Würzburg, Germany)

  Altered amino acid metabolism in response to dysfunctional mitochondria in Barth Syndrome cardiomyopathy

  16:20-16:30

  Short talk: Ujang Purnama (Oxford, United Kingdom)

  Activation of HIF-1α rescues the hypoxic response and reverses metabolic dysfunction in the diabetic heart

  16:30-17:00

  Tech Advances 1

  Chair: Marten Szibor (Jena, Germany) & Tímea Komlódi (Innsbruck, Austria)

  16:30-16:45

  Moa Persson (Symcel, Sweden)

  Measuring metabolism through isothermal microcalorimetry and how it can help to reveal novel and crucial insights on cellular response

  16:45-17:00

  Claudia Prothmann (Merck Chemicals GmbH, Germany)

  Synthetic CRISPR – a fast, flexible and customizable solution for difficult to transfect cells

  17:00-17:15

  Break

  17:15-18:15

  Session 2

  Chairs: Josh Butcher (Stillwater, OK, USA) & Benjamin Lauzier (Nantes, France)

  17:15-17:35

  Natascha Sommer (Giessen, Germany)

  The role of the mitochondrial respiratory chain in oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction

  17:35-17:55

  José López-Barneo (Seville, Spain)

  The role of the mitochondrial respiratory chain in acute oxygen sensing in arterial chemoreceptors

  17:55-18:05

  Short talk: Stephanie Kereliuk (Winnipeg, Canada)

  Multi-omics profiling implicates impaired mitochondrial oxidative metabolism as a mechanism of cardiometabolic disease development in rat offspring exposed to gestational diabetes

  18:05-18:15

  Short talk: Leigh Goedeke (New Haven CT, USA)

  SGLT2 inhibition promotes myocardial ketone utilization in the normal and failing heart

  18:15-18:45

  Tech Advances 2

  Chair: Adam Wende (Birmingham, AL, USA)

  18:15-18:30

  Werner Kammerloher (Agilent Technologies, Germany)

  Using Seahorse Assays to measure the cellular energy metabolism in cardiovascular research

  18:30-18:45

  Erich Gnaiger (Oroboros Instruments, Austria)

  Coenzyme Q redox state and high-resolution respirometry: Novel perspectives for mitochondrial diagnostics

  18:45-19:00

  Break

  19:00-20:00

  Session 3

  Chairs: Qutuba Karwi (Alberta, Canada) & Christine Des Rosiers (Montreal, Canada)

  19:00-19:20

  Hyoung Kyu Kim (Busan, Korea)

  A novel cardiac contractility regulator in energy metabolism and calcium signaling

  19:20-19:40

  Lisa Heather (Oxford, United Kingdom)

  Targeted rescue of dysfunctional energetics in the diabetic heart

  19:40-19:50

  Short talk: Mathieu Panel (Montpellier, France)

  Impaired mitochondrial calcium homeostasis at the early stage of the diabetic cardiomyopathy

  19:50-20:00

  Short talk: Edgar Nollet (Amsterdam, The Netherlands)

  Mitochondrial dysfunction and metabolic profiling in septal myectomy tissue of patients with obstructive hypertrophic cardiomyopathy

  20:00-open end

  ePoster session

• 14:00-14:30

  Outlook 2022

  Chair: Helen Collins (Louisville, KY, USA)

  The next organising committee

  Teaser presentation of the upcoming meeting in Seoul 2022

  14:30-15:30

  Keynote Lecture 2

  Chair: Véronique-Anne Lacombe (Oklahoma City, OK, USA)

  Deborah Muoio (Durham, NC, USA)

  Metabolic flexibility and mitochondrial gridlock

  15:30-16:30

  Session 4

  Chairs: Christina Schenkl (Jena, Germany) & José Antonio Enríquez (Madrid, Spain)

  15:30-15:50

  Satoaki Matoba (Kyoto, Japan)

  Changes in cardiac metabolism during diabetes and heart failure

  15:50-16:10

  Lea M. Durham Delbridge (Melbourne, Australia)

  Cardiac adventures in glycophagy – a novel metabolic defect in diabetic cardiomyopathy

  16:10-16:20

  Short talk: Mark Pepin (Heidelberg, Germany)

  The δC isoform of Ca²⁺/calmodulin-dependent protein kinase II regulates pressure overload-induced reprogramming of cardiac metabolic substrate switching in mice

  16:20-16:30

  Short talk: Julia Möllmann (Aachen, Germany)

  The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis

  16:30-17:00

  Tech Advances 3

  Chair: Marten Szibor (Jena, Germany)

  16:30-16:45

  Dieter Fuchs (FUJIFILM VisualSonics, Germany)

  State of the Art for HF Ultrasound and Photoacoustics

  16:45-17:00

  Claudia Oerther (Bruker, Germany)

  Preclinical cardiac MR imaging beyond your imagination

  17:00-17:15

  Break

  17:15-18:15

  Session 5

  Chairs: Estelle Heyne (Jena, Germany) & Ilka Wittig (Frankfurt, Germany)

  17:15-17:35

  Luc Bertrand (Brussels, Belgium)

  AMPK and O-GlcNAcylation, a novel metabolic partnership in cardiovascular diseases

  17:35-17:55

  José Antonio Enríquez (Madrid, Spain)

  Heteroplasmy of wild type mitochondrial DNA variants in mice causes metabolic heart disease with pulmonary hypertension and frailty

  17:55-18:05

  Short talk: Sathya Velmurugan (Lexington, KY, USA)

  Inhibition of Na⁺–glucose cotransporter 1 reduces arrhythmogenesis in diabetic rats

  18:05-18:15

  Short talk: Helena Kenny (Iowa City, IA, USA)

  Cardiac specific deletion of the citrate carrier is associated with stress induced cardiac dysfunction

  18:15-18:30

  Break

  18:30-20:00

  Session 6

  Chairs: Florin Despa (Lexington, KY, USA) & Terje Larsen (Tromsø, Norway)

  18:30-19:30

  Finalists of the "William C. Stanley" Early Investigator Awards, selected from pitches submitted by junior investigators

  Kaitlyn Dennis (Oxford, United Kingdom)

  Diabetic mitochondria are resistant to palmitoyl CoA inhibition of respiration, which is detrimental during ischaemia

  Justine Dontaine (Brussels, Belgium)

  AMPK and O-GlcNAcylation: a new paradigm to protect the failing heart

  Velmurugan Gopal Viswanathan (Lexington, KY, USA)

  Diabetic cardiomyopathy is partially reversed by knocking-down human amylin in mice with conditional expression of human amylin in the pancreatic β-cells

  Estelle Heyne (Jena, Germany)

  Exercise training but not high genetically determined exercise capacity alone is related to reduced cardiac ischemia-reperfusion injury

  Qutuba Karwi (Alberta, Canada)

  Branched-chain aminotransferase deletion worsens adverse remodelling in heart failure

  Alice Marino (Brussels, Belgium)

  Sodium myo-inositol cotransporter affects cardiac hypertrophy and fibrosis in pressure-overloaded mouse hearts

  19:30-19:45

  Online voting & awarding 3x "William C. Stanley" Early Investigator Awards

  19:45-20:00

  Concluding remarks

  20:30-22:00

  Reception for face-to-face participants

• ePoster session

  P.1 Adam Abdulkareem (Uttar Pradesh, India)
  Letrozole ameliorated lipids and uric acid accumulations in male Wistar rats exposed to high fructose intake
  
  P.2 Abdalla Ahmed (Toronto, Canada)
  Lysine demethylase 8 epigenetically regulates cardiac metabolism to prevent myocardial deterioration in heart failure
  
  P.3 Sayan Bakshi (Birmingham, AL, USA)
  Epigenetic regulation of atrial natriuretic peptide (ANP) associates with distinct race-specific ischemic heart failure severity
  
  P.4 Shrijith Balasundararajan (Vestavia Hills, AL, USA)
  Chitinase regulation in heart tissue associated with diabetes and heart failure
  
  P.5 Kristina Bardova (Prague, Czech Republic)
  Whole-body and adipose tissue metabolic flexibility correlates with genetically-determined resistance to obesity in mice
  
  P.6 Charlotte Betus (Nantes, France)
  O-GlcNAcylation increase ATP-citrate lyase multimerization
  
  P.7 Taylor Billingsley (Auburn, AL, USA)
  Enhanced expression of adiponectin, C1Q and collagen domain containing (ADIPOQ) in heart failure and its potential role in diabete
  
  P.8 Neoma Boardman (Tromsø, Norway)
  High palmitate alters glutathione redox during severe oxidant stress in the heart
  
  P.9 Laurent Bultot (Brussels, Belgium)
  Increase in protein acetylation, a hallmark of cardiac metabolic stress by metabolic overfueling. The example of cardiac glucose uptake inhibition by fatty acids
  
  P.11 Samuel Chang (Birmingham, AL, USA)
  Role of chronic O-GlcNAcylation in cardiac hypertrophy by calcium dependent protein kinase type II beta (CaMKIIβ) and NADPH oxidase 4 (Nox4)
  
  P.12 Ahmad Cluntun (Salt Lake City, UT, USA)
  The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure
  
  P.13 Helen Collins (Louisville, KY, USA)
  Changes in the metabolome and transcriptome of the maternal heart during pregnancy
  
  P.14 Mariana Diniz (Coimbra, Portugal)
  Preventing cardiac disease: maternal gestational exercise to mitigate obesity-induced cardiac metabolic impairment in the offspring.
  
  P.15 Thomas Dupas (Nantes, France)
  The O-GlcNAc stimulation increase cardiac O-GlcNAcylated proteins without affecting genes transcription
  
  P.16 Kyle Fulghum (Louisville, KY, USA)
  Phosphofructokinase-mediated metabolic channeling in the heart
  
  P.17 Claudia Garcia Castro (Giessen, Germany)
  The role of p66shc in biological aging of the lung
  
  P.19 Mareike Gierhardt (Buenos Aires, Argentina)
  Mitochondrial proteins p66shc and CypD regulate pulmonary vascular contractility via cellular calcium homeostasis
  
  P.20 Chae-Myeong Ha (Birmingham, AL, USA)
  Protein acetylation regulation via specific pyruvate dehydrogenase kinase (PDK) isozymes in the heart
  
  P.21 Chaoshan Han (Birmingham, AL, USA)
  Metabolic labeling of cardiomyocyte-derived exosomal RNAs identifies miR-208 as a mediator of heart-lung crosstalk
  
  P.22 Pablo Hernansanz-Agustín (Madrid, Spain)
  Na⁺ controls hypoxic redox signalling through the mitochondrial electron transport chain
  
  P.23 James Hobkirk (Hull, United Kingdom)
  Human left ventricular intramyocardial lipid droplets in patients with coronary ischemia and type 2 diabetes
  
  P.24 Kirsten Jansen (Tromsø, Norway)
  Hydrolysed wax ester from Calanus oil protects H9c2 cardiomyoblasts from palmitate-induced lipotoxicity
  
  P.25 Ying Jiang (Birmingham, AL, USA)
  Sam68 promotes compensatory cardiac hypertrophy in mice
  
  P.26 Dhanalakshmi Jothi (Jena, India)
  NIT1 acts as a repressor of FoxO3a-dependent stress resistance
  
  P.27 Helena Kenny (Iowa City, IA, USA)
  Cardiac specific overexpression of transcription factor EB (TFEB) in normal hearts induces pathologic cardiac hypertrophy and lethal cardiomyopathy
  
  P.28 Alice Knapton (Cambridge, United Kingdom)
  A method for measuring mitochondrial respiratory capacity in frozen rat cardiac samples
  
  P.29 Tímea Komlódi (Innsbruck, Austria)
  Hydrogen peroxide production, mitochondrial membrane potential and the redox state of the coenzyme Q measured at tissue normoxia and hyperoxia in heart mitochondria
  
  P.30 Amber Korn (Amsterdam, Netherlands)
  Liraglutide treatment attenuates dysfunction-related changes in the cardiac and cerebral microvasculature in streptozotocin-induced diabetic rats
  
  P.31 Deepak Kotiya (Lexington, KY, USA)
  Systemic amylin dyshomeostasis leads to metabolic dysfunction and affects cognition
  
  P.32 Aneta Kowalski (Pittsburgh, PA, USA)
  Crebrf regulates cardiomyocyte bioenergetics and survival
  
  P.33 Chi Fung Lee (Oklahoma City, OK, USA)
  Regulations of NAD metabolism in metabolic cardiomyopathy (MC)
  
  P.34 Selma Lopez Vaquera (Châtenay-Malabry, France)
  Impact of nicotinamide riboside NAD precursor treatment on cardiac remodeling after myocardial infarction in rat
  
  P.35 Jubert Marquez (Busan, South Korea)
  Phosphorylation of novel tyrosine residues in mitochondrial creatine kinase confers cardioprotection against hypoxia/reoxygenation injury
  
  P.36 Allison Meadows (Bethesda, MD, USA)
  Fasting and re-feeding generate distinct metabolites that modulate immunity linked to cardiovascular risk
  
  P.37 Lauriane Michel (Brussels, Belgium)
  Cardiac beta3-adrenergic receptors increase pentose phosphate pathway flux and protect against hypertrophic remodeling by reducing oxidative stress under haemodynamic stress
  
  P.38 Alex Milliken (Rochester, NY, USA)
  Blocking succinate release enhances mitochondrial reactive oxygen species generation and worsens ischemia-reperfusion injury
  
  P.39 Kevin Monceaux (Châtenay-Malabry, France)
  Identification of natural phenolic compound protecting the heart from severe ER stress through the SIRT1-mediated deacetylation of eIF2α
  
  P.40 Emily Nunan (Stillwater, OK, USA)
  Targeting myostatin as an adjunct treatment for preservation of cardiometabolic and skeletal muscle munction in type 1 diabetes
  
  P.41 Sean Raph (Louisville, KY, USA)
  Mechanisms underlying physiologic coupling of myocardial metabolism and blood flow
  
  P.42 Sangmi Ock (Seoul, South Korea)
  IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting αSMA
  
  P.43 Mariola Olkowicz (Krakow, Poland)
  Metabolomic biosignature of vascular response to dyslipidaemia investigated with a unique analytical approach based on Solid-Phase Microextraction
  
  P.44 Thomas Pelé (Nantes, France)
  Modulation of O-GlcNAcylation and carbonic anhydrase in response to stress induced by cardiopulmonary bypass
  
  P.45 Andrea Pereyra (Greenville, SC, USA)
  Differential metabolism of octanoate by liver, heart and muscle and the failure to rescue cardiomyopathy in CPT2 deficiency
  
  P.46 Kaya Persad (Edmonton, Canada)
  Maturation of cardiomyocytes is associated with a decrease in the Warburg effect due primarily to a decrease in glycolysis
  
  P.47 Linda Peterson (St. Louis, MO, USA)
  Sodium glucose cotransporter (SGLT2) expression is associated with worse survival and more aggressive prostate and colon cancer
  
  P.48 Julie Pires da Silva (Aurora, CO, USA)
  Serum from pediatric dilated cardiomyopathy patients promotes dysregulation of cardiolipin biosynthesis and mitochondrial dysfunction in primary cardiomyocytes
  
  P.49 Luke Potter (Birmingham, AL, USA)
  Transcriptional and DNA methylation changes underly metabolic alterations in diabetic African American heart failure patients
  
  P.51 Aijun Qiao (Birmingham, AL, USA)
  Ablation of hepatic Sam68 protects against hypercholesterolemia and atherosclerosis
  
  P.52 Gabriel Reimann (Jena, Germany)
  UQCRH-KO mediated defect in Complex III activity led to a shift towards anaerobic metabolism and cardiac insulin resistance associated with loss of metabolic flexibility
  
  P.53 Moritz Reiter (Jena, Germany)
  Xenotopic expression of the complex I bypass protein Ndi1 may deplete cardiac fatty acid oxidation without impairing cardiac contractile function
  
  P.54 Julie Rennison (Cleveland, OH, USA)
  Coexpression analysis of putative AF risk genes identifies mitochondrial pathways associated with propionyl CoA carboxylase β expression in human left atria
  
  P.55 Matthew Rochowski (Stillwater, OK, USA)
  The cardiac SERCA pump modulates whole–body glucose homeostasis through a protein disulfide isomerase-dependent pathway
  
  P.56 Michele Russo (Turin, Italy)
  Phosphoinositide 3-kinase gamma at the crossroad between autophagy and metabolic control in doxorubicin-induced cardiomyopathy
  
  P.57 Linda Sasset (New York, NY, USA)
  Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure
  
  P.58 Christina Schenkl (Jena, Germany)
  High and low intrinsic exercise capacity and exercise training in cardiac pressure overload
  
  P.59 Francesco Schianchi (Maastricht, Netherlands)
  Protein hyper-palmitoylation contributes to cardiac lipid-induced insulin resistance
  
  P.60 Rui Shang (Vancouver, Canada)
  Cardiac-specific VEGFB transgene reduces lipoprotein lipase activity and improves insulin signaling in rat heart
  
  P.61 Bahgat Soilih Abdoul Karim (Châtenay-Malabry, France)
  Vasorelaxant and anti-proliferative effects of leflunomide
  
  P.62 Alice Sowton (Cambridge, United Kingdom)
  Long-term dietary inorganic nitrate supplementation lessens cardiac triacylglycerol accumulation in metabolic syndrome and alters the pericardial fat lipidome
  
  P.63 Alena Spagnolo (Jena, Germany)
  Skeletal muscle but not cardiac mitochondria as mediator for a shorter lifespan in rats with lower intrinsic exercise capacity
  
  P.64 Felix Stadler (Würzburg, Germany)
  The role of mitochondrial creatine kinase (mt-CK) in ROS stabilisation
  
  P.65 Marten Szibor (Jena, Germany)
  Alternative oxidase expression impairs long-term adaptive remodeling following cardiac ischemia
  
  P.66 Xiaoqiang Tang (Chengdu, China)
  Acylations in Cardiometabolic Diseases, the Advances and Perspectives
  
  P.67 Tint Tha Ra Wun (Old Wesbury, NY, USA)
  P21-activated kinase 1 (PAK1) is both sufficient and necessary for autophagy flux in H9c2 cardiomyoblast cells
  
  P.68 Kerstin Timm (Oxford, United Kingdom)
  AICAR prevents doxorubicin-induced heart failure in rats
  
  P.69 Carolina Tocantins (Cantanhede, Portugal)
  Maternal cardiac mitochondrial alterations induced by gestational diabetes mellitus prevail at 8 weeks postpartum
  
  P.70 Jan-Niklas Tomczak (Frankfurt, Germany)
  Inspection and service on mitochondrial complexes ensure bioenergetic function in postmitotic tissues
  
  P.71 Ettore Vanni (Geneva, Switzerland)
  Can a droplet of lipids save your heart?
  
  P.72 Upasna Varma (Melbourne, Australia)
  Metformin treatment prevents diastolic dysfunction and cardiac lipid accumulation in type 1 diabetes
  
  P.73 Nirmal Verma (Lexington, KY, USA)
  Amylin deposition in skin capillaries as a marker for cerebral small vessel disease
  
  P.74 Joseph Visker (Salt Lake City, UT, USA)
  The role of mitochondrial pyruvate carrier (MPC) on myocardial salvage following acute myocardial infarction
  
  P.75 Rachel Weiss (St. Louis, MO, USA)
  Deletion of the mitochondrial pyruvate carrier enhances glycolysis and mTOR activation which drives cardiac hypertrophy and failure
  
  P.76 David Weissman (Würzburg, Germany)
  Impact of Fabry disease-causing mutations on excitation-contraction coupling and mitochondrial functions of cardiac myocyte
  
  P.77 Myrthe Willemars (Maastricht, Netherlands)
  Phosphatidylinositol 4-kinase IIIβ as a target to prevent cardiac hypertrophy-induced contractile dysfunction
  
  P.78 Yang Xiao (Amsterdam, Netherlands)
  Only the NAD precursor nicotinamide riboside maintains cardioprotection under clinically relevant conditions, possibly through activation of glycolysis and autophagy
  
  P.79 Anton Xu (Würzburg, Germany)
  Energetic uncoupling in human cardiomyopathy: interplay between hypercontractility and oxidation of myofilament creatine kinase
  
  P.80 Karishma Yasmin (Koraput, India)
  Prevalence and determinants of cardiometabolic syndrome: a perspective